Maternal serum cytokines at 30-33weeks in the prediction of preeclampsia

Prenatal Diagnosis

Volumn 33, Issue 9, 2013, Pages 823-830

  Mosimann, Beatrice ^a   Wagner, Marion ^a   Poon, Leona C Y ^a,b   Bansal, Amolak S ^c   Nicolaides, Kypros H ^a,d  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c ST HELIER HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FETAL WELL BEING; FETUS ECHOGRAPHY; FETUS GROWTH; GESTATIONAL AGE; HUMAN; MATERNAL HYPERTENSION; MATERNAL SERUM; PREECLAMPSIA; PREGNANCY OUTCOME; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROTEINURIA; THIRD TRIMESTER PREGNANCY;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; INFANT, NEWBORN; INFLAMMATION MEDIATORS; MOTHERS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, THIRD; PROGNOSIS;

EID: 84883459722     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4129     Document Type: Article

References (37)

1. World Health Organization. Make Every Mother Child Count. World Health Report, 2005. Geneva, Switzerland: World Health Organization, 2005.
2. Confidential Enquiry into Maternal and Child Health (CEMACH) Perinatal Mortality 2006: England, Wales and Northern Ireland. London, United Kingdom: CEMACH; 2008.
3. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130-7.
4. Pijnenborg R. The placental bed. Hypertens Pregnancy 1996;15:7-23.
5. Meekins JW, Pijnenborg R, Hanssens M, et al. A study of placental bed spiral arteries and trophoblastic invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynecol. 1994;101:669-74.
6. De Wolf F, Robertson WB, Brosens I. The ultrastructure of acute atherosis in hypertensive pregnancy. Am J Obstet Gynecol 1975;123:164-74.
7. Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynecol. 1986;93:1049-59.
8. Granger JP, Alexander BT, Llinas MT, et al. Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension 2001;38:718-22.
9. Redman CW. Pre-eclampsia and the placenta. Placenta 1991;12:301-8.
10. Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993;341:1447-51.
11. Dekker GA, Sibai B. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 1998;179:1359-75.
12. Stark JM. Pre-eclampsia and cytokine induced oxidative stress. Br J Obstet Gynaecol 1993;100:105-9.
13. Conrad KP, Benyo DF. Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol 1997;37:240-9.
14. Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1988;158:892-98.
15. Siawaya JFD, Roberts T, Babb C, et al. An evaluation of commercial fluorescent bead-based Luminex cytokine assays. PLoS One 2008;3(7):e2535.
16. Malekzadeh A, de Groot V, Beckerman H, et al. Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. Methods 2012;56:508-13.
17. Thompson DK, Huffman KM, Kraus WE, Kraus VB. Critical appraisal of four IL-6 immunoassays. PLoS One 2012;7(2):e30659.
18. The Cytokine Handbook. Thompson A (Ed.). Academic Press: London, 1998.
19. Saito S, Shiozaki A, Nakashima A, et al. The role of the immune system in preeclampsia. Mol Aspects Med 2007;28:192-209.
20. Dinarello CA. Proinflammatory cytokines. Chest 2000;118:503-8.
21. Feghali CA, Writh TM. Cytokines in acute and chronic inflammation. Front Biosci 1997;2:d12-26.
22. Rice A, Chard T. Cytokines in implantation. Cytokine Growth Factor Rev 1998;9, 287-96.
23. Saito, S. Cytokine cross-talk between mother and the embryo/placenta. J Reprod Immunol 2001;52, 15-33.
24. Keelan JA, Mitchell MD. Placental cytokines and preeclampsia. Front Biosci 2007;12:2706-27.
25. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999;180:499-506.
26. Kronborg CS, Gjedsted J, Vittinghus E, et al. Longitudinal measurement of cytokines in pre-eclamptic and normotensive pregnancies. Acta Obstet Gynecol Scand 2011;90:791-6.
27. Mosimann B, Wagner M, Birdir C, et al. Maternal serum tumour necrosis factor receptor 1 (TNF-R1) at 30-33weeks in the predicition of preeclampsia. J Matern Fetal Neonatal Med. 2012 Dec 3. [Epub ahead of print]
28. Kucukgoz GU, Tuncay OF, Baris GA, et al. An analysis of C-reactive protein, procalcitonin, and d-Dimer in pre-eclamptic patients. Am J Reprod Immunol 2012;68:331-337.
29. Savvidou MD, Lees CC, Para M, et al. Levels of C-reactive protein in pregnant women who subsequently develop pre-eclampsia. Br J Obstet Gynecol. 2002;109:297-301.
30. Gandevani SB, Banaem LM, Mohamadi B, et al. Association of high-sensitivity C-reactive protein serum levels in early pregnancy with the severity of preeclampsia and fetal birth weight. J Perinat Med 2012;0:1-5.
31. Rasanen J, Girsen A, Lu X, et al. Comprehensive maternal serum proteomic profiles of preclinical and clinical preeclampsia. J Proteome Res 2010;9:4274-81.
32. Abumaree MH, Chamley LW, Badri M, El-Muzaini MF. Trophoblast debris modulate the expression of immune proteins in macrophages: a key to maternal tolerance of the fetal allograft? J Reprod Immunol 2012;94:131-41.
33. Sargent IL, Borzychowski AM, Redman CW. Immunoregulation in normal pregnancy and pre-eclampsia: an overview. Reprod Biomed Online 2006;5:680-6.
34. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83.
35. Akolekar R, de Cruz J, Foidart JM, et al. Maternal plasma soluble fms.like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13weeks of gestation in preeclamsia. Prenat Diagn 2010;30:191-7.
36. Lai J, Pinas A, Poon LC, et al. Maternal serum placental growth factor, pregnancy-associated plasma protein-A and free ß-human chorionic gonadotrophin at 30-33weeks in the prediction of preeclampsia. Fetal Diagn Ther. 2013 Feb 20. [Epub ahead of print]
37. Savoia C, Schiffrin EL. Inflammation in hypertension. Curr Opin Nephrol Hypertens 2006;15:152-8.